{'fraction_non_alphanumeric': 0.020833333333333332, 'fraction_numerical': 0.020833333333333332, 'mean_word_length': 5.5246913580246915, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Anti-Hsp20 antibody concentrations inversely correlated with tumor progression in ovarian cancer.

PURPOSE
To investigate the serum concentrations of anti-heat shock protein 20 (anti-Hsp20) antibodies in women with ovarian cancer at different clinical stages, and the relationship between these concentrations and tumor progression.


MATERIALS AND METHODS
Blood samples were obtained from 72 patients undergoing surgery for ovarian cancer, 21 women with ovarian carcinoid, and 42 healthy women. Anti-Hsp20 antibody concentrations were determined by enzyme-linked immunosorbent assay.


RESULTS
Mean anti-Hsp20 antibody concentrations were significantly lower in patients with ovarian cancer than in the control group. The anti-Hsp20 antibody concentrations were negatively correlated with ovarian cancer malignancy.


CONCLUSIONS
The present findings suggest that anti-Hsp20 antibodies may play a protective role against ovarian cancer progression, and that anti-Hsp20 antibodies may be a new index for the early diagnosis and treatment of ovarian cancer.